Special Issue

Advances in Radiopharmaceuticals: Enhancing Targeted Delivery, Disease Diagnosis, and Therapeutic Applications

Message from the Guest Editors

Radiopharmaceuticals are designed to target either tumor- or non-tumor-associated tissues, delivering single or paired radioactive atoms based on specific diagnostic or therapeutic needs. The selection of ligands—such as proteins, peptides, antibodies, nanoparticles, and drugs—depends on the chosen radioactive atom and the intended target tissue, allowing for the targeting of a wide range of tissues. Additionally, the diversity of radioactive atoms, characterized by variations in energy type, density, and half-life, plays a crucial role in effectively targeting tissues while facilitating the diagnosis and treatment of numerous diseases. This Special Issue aims to underscore the capabilities of ligands and radioactive atoms in diagnosing and treating diseases through innovative approaches or by integrating existing methods with synergistic elements.

Guest Editors

Dr. Kuan Hu

- 1. National Institutes for Quantum Science and Technology, Chiba, Japan
- 2. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Dr. Volkan Tekin

Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

Deadline for manuscript submissions

31 December 2025



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/236098

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, New Jersey 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

